Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Upstart Holdings Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M), while Upstart Holdings Inc trades at $22.3 (market cap $2.21B). The key difference: Upstart Holdings Inc is far larger — about 2.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Upstart Holdings Inc for 39 Days on average.
| MRVI | UPST | |
|---|---|---|
Market Cap | $977.37M | $2.21B |
Volume | 2,742,564 | 5,011,542 |
Sector | Health | Financials |
52-Week High | $9.00 | $52.74 |
52-Week Low | $2.83 | $22.74 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $1.08B | $3.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
UPST trades at $23.83, up 0.34% on the day but remains in a bearish technical trend. The company achieved profitability in 2025 with $1.02B revenue and $53.6M net income, though recent quarters show earnings misses. Analyst consensus is mixed with a $38.13 price target, while technical indicators signal caution with bearish moving averages and neutral oscillators.
The outlook balances AI-driven lending growth potential against execution risks and volatile cash flows. Key opportunities include expanding partnerships and securitization deals, while risks involve credit market sensitivity and rising debt levels. The stock trades at a premium valuation despite recent operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
